GSK/Genmab's Arzerra gives response in refractory leukaemia
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline/Genmab's Arzerra (ofatumumab) has shown high partial response rates in heavily pretreated patients with chronic lymphocytic leukaemia (CLL), the companies said at the recent American Society of Hematology (ASH) meeting in San Francisco.